Virus-like Particles As Vaccines for Allergen-Specific Therapy: An Overview of Current Developments

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jul 13

PMID 39000536

Authors

Helena Berreiros-Hortala

Gonzalo Vilchez-Pinto

Araceli Diaz-Perales

Maria Garrido-Arandia

Jaime Tome-Amat

Affiliations

Soon will be listed here.

Abstract

Immune engineering and modulation are the basis of a novel but powerful tool to treat immune diseases using virus-like particles (VLPs). VLPs are formed by the viral capsid without genetic material making them non-infective. However, they offer a wide variety of possibilities as antigen-presenting platforms, resulting in high immunogenicity and high efficacy in immune modulation, with low allergenicity. Both animal and plant viruses are being studied for use in the treatment of food allergies. These formulations are combined with adjuvants, T-stimulatory epitopes, TLR ligands, and other immune modulators to modulate or enhance the immune response toward the presented allergen. Here, the authors present an overview of VLP production systems, their immune modulation capabilities, and the applicability of actual VLP-based formulations targeting allergic diseases.

References

Foerster J, Moleda A . Virus-Like Particle-Mediated Vaccination against Interleukin-13 May Harbour General Anti-Allergic Potential beyond Atopic Dermatitis. Viruses. 2020; 12(4). PMC: 7232523. DOI: 10.3390/v12040438. View

Durham S, Shamji M . Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2022; 23(5):317-328. PMC: 9575636. DOI: 10.1038/s41577-022-00786-1. View

Pechsrichuang P, Namwongnao S, Jacquet A . Bioengineering of Virus-like Particles for the Prevention or Treatment of Allergic Diseases. Allergy Asthma Immunol Res. 2020; 13(1):23-41. PMC: 7680827. DOI: 10.4168/aair.2021.13.1.23. View

Barber D, Diaz-Perales A, Escribese M, Kleine-Tebbe J, Matricardi P, Ollert M . Molecular allergology and its impact in specific allergy diagnosis and therapy. Allergy. 2021; 76(12):3642-3658. DOI: 10.1111/all.14969. View

Veneziano R, Moyer T, Stone M, Wamhoff E, Read B, Mukherjee S . Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat Nanotechnol. 2020; 15(8):716-723. PMC: 7415668. DOI: 10.1038/s41565-020-0719-0. View

Hughes K, Saunders M, Landers J, Janczak K, Turkistani H, Rad L . Masked Delivery of Allergen in Nanoparticles Safely Attenuates Anaphylactic Response in Murine Models of Peanut Allergy. Front Allergy. 2022; 3:829605. PMC: 8974743. DOI: 10.3389/falgy.2022.829605. View

Lin Y, Zimmermann J, Schulke S . Novel adjuvants in allergen-specific immunotherapy: where do we stand?. Front Immunol. 2024; 15:1348305. PMC: 10920236. DOI: 10.3389/fimmu.2024.1348305. View

Wang Y, Douglas T . Bioinspired Approaches to Self-Assembly of Virus-like Particles: From Molecules to Materials. Acc Chem Res. 2022; 55(10):1349-1359. DOI: 10.1021/acs.accounts.2c00056. View

Vicente T, Roldao A, Peixoto C, Carrondo M, Alves P . Large-scale production and purification of VLP-based vaccines. J Invertebr Pathol. 2011; 107 Suppl:S42-8. PMC: 7094596. DOI: 10.1016/j.jip.2011.05.004. View

10.

Missaoui K, Gonzalez-Klein Z, Pazos-Castro D, Hernandez-Ramirez G, Garrido-Arandia M, Brini F . Plant non-specific lipid transfer proteins: An overview. Plant Physiol Biochem. 2022; 171:115-127. DOI: 10.1016/j.plaphy.2021.12.026. View

11.

Jensen-Jarolim E, Bachmann M, Bonini S, Jacobsen L, Jutel M, Klimek L . State-of-the-art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2019; 75(4):746-760. DOI: 10.1111/all.14134. View

12.

Zepeda-Cervantes J, Ramirez-Jarquin J, Vaca L . Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs. Front Immunol. 2020; 11:1100. PMC: 7297083. DOI: 10.3389/fimmu.2020.01100. View

13.

Wu C, Yeh Y, Yang Y, Chou C, Liu M, Wu H . Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One. 2010; 5(3):e9784. PMC: 2842297. DOI: 10.1371/journal.pone.0009784. View

14.

Orengo J, Radin A, Kamat V, Badithe A, Ben L, Bennett B . Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018; 9(1):1421. PMC: 5897525. DOI: 10.1038/s41467-018-03636-8. View

15.

Curin M, Khaitov M, Karaulov A, Namazova-Baranova L, Campana R, Garib V . Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches. Curr Allergy Asthma Rep. 2018; 18(7):39. PMC: 5994214. DOI: 10.1007/s11882-018-0790-x. View

16.

Lua L, Connors N, Sainsbury F, Chuan Y, Wibowo N, Middelberg A . Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2013; 111(3):425-40. DOI: 10.1002/bit.25159. View

17.

Gerlich W . "Dual use": The anti-allergy vaccine BM32 and its HBV carrier protein. EBioMedicine. 2020; 60:102998. PMC: 7516070. DOI: 10.1016/j.ebiom.2020.102998. View

18.

Pacios L, Sanchez F, Ponz F . Intrinsic disorder in the dynamic evolution of structure, stability, and flexibility of potyviral VLP assemblies: A computational study. Int J Biol Macromol. 2023; 254(Pt 2):127798. DOI: 10.1016/j.ijbiomac.2023.127798. View

19.

Pietersen I, van Zyl A, Rybicki E, Hitzeroth I . Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants. Pathogens. 2020; 9(12). PMC: 7760623. DOI: 10.3390/pathogens9120996. View

20.

Kim K, Kim G, Bae J, Song J, Kim H . A pH-Responsive Virus-Like Particle as a Protein Cage for a Targeted Delivery. Adv Healthc Mater. 2023; 13(4):e2302656. PMC: 11469083. DOI: 10.1002/adhm.202302656. View